Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAINIER Phase 3 study of povetacicept in adults with immunoglobulin A nephropathy
2024-514135-17-00Phase 3Authorised
- Sponsor
- Alpine Immune Sciences, Inc.
- Start
- Nov 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial in IgA nephropathy (IgAN) comparing Povetacicept with Placebo (2 arms). Primary endpoints: Change from baseline in 24-hour urine protein to creatinine ratio at Week 36, Total estimated glomerular filtration rate slope through Week 104 and 1 more. Planned start Nov 2024; status: authorised.
02
Drugs
povetacicept
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2024-514135-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514135-17-00.